Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00104-016-0323-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis.
Eur J Neurol
March 2025
Department of Neurology & Rehabilitation Medicine, The George Washington University, Washington, DC, USA.
Background: Thymectomy is beneficial for treating early-onset acetylcholine receptor antibody-positive myasthenia gravis (MG); however, its effects on late-onset MG (LOMG) remain less well understood. Given the increasing incidence of MG among the population 50 years old and above, addressing the question of whether thymectomy is effective for this age group is critically important. This study aimed to assess the present evidence for the efficacy of thymectomy in LOMG and identify potential characteristics that may predict the treatment response.
View Article and Find Full Text PDFClinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study.
Cureus
January 2025
Neurology, St. Lukes Medical Center, Quezon City, PHL.
Background: Myasthenia gravis (MG) is an autoimmune disorder causing muscle weakness, with 10%-20% of cases becoming refractory to standard treatments. Rituximab, a CD20-targeting monoclonal antibody, has shown promise in refractory MG but lacks data from low- and middle-income countries (LMICs), such as the Philippines.
Methods: A retrospective, cross-sectional study was conducted in treatment-refractory MG patients in St.
Myasthenia gravis in 2025: five new things and four hopes for the future.
J Neurol
February 2025
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). Beginning with the randomized trial of thymectomy in myasthenia gravis that demonstrated efficacy of thymectomy in nonthymomatous MG, several new treatment approaches have completed successful clinical trials and regulatory launch. These modalities, including B cell depletion, complement inhibition, and blockade of the neonatal Fc receptor, are now in use, offering prospects of sustained remission and neuromuscular protection in what is a long-term disease.
View Article and Find Full Text PDFThoracoscopic management of giant thymolipoma.
Indian J Thorac Cardiovasc Surg
March 2025
Institute of Child Health and Hospital for Children, Madras Medical College Hospital, Chennai, India.
Thymolipomas are rare benign thymic neoplasms that contribute 2 to 9% of thymic tumors. Surgical excision remains the primary treatment, with video-assisted thoracoscopic surgery (VATS) emerging as a valuable approach. Less than 50 cases of pediatric thymolipomas have been reported, with the youngest case documented at 6 months of age, and fewer than five pediatric cases have been managed using the thoracoscopy approach in the literature.
View Article and Find Full Text PDFPredictive Value of Perioperative Blood Lactic Acid Levels for Postoperative Crisis in Myasthenia Gravis Patients Undergoing Thymectomy.
Muscle Nerve
February 2025
Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
Introduction/aims: Postoperative myasthenic crisis (POMC), which occurs specifically after thymectomy in myasthenia gravis (MG) patients, is a serious complication with known risk factors such as prior myasthenic crisis. However, the predictive value of perioperative blood lactic acid levels (BLAL) for POMC remains unclear. This study aims to determine whether changes in perioperative BLAL can predict POMC in MG patients undergoing thymectomy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!